Literature DB >> 7831533

Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component.

O T Lampejo1, D M Barnes, P Smith, R R Millis.   

Abstract

Recently there has been an increase in the detection of DCIS, and there is much interest in establishing a new pathologic classification that has less subjective criteria than traditional methods and that more closely reflects the clinical behavior of the tumor. It is hoped that this will lead to a more rational approach to treatment of DCIS. In this study one such recently proposed classification has been applied to the DCIS component of 215 infiltrating ductal carcinomas, and this has been compared with the histologic grade of the tumors. There was a highly significant correlation between DCIS type and grade (chi 2 = 110.0, P < 0.0001); well- and intermediately differentiated DCIS were usually found in grade I and grade II tumors, respectively. Poorly differentiated DCIS was equally associated with grade II and grade III infiltrating carcinomas. Furthermore, in univariate analysis, the DCIS type correlated with disease-free (chi 2 = 17.1, P < 0.001) and overall survival (chi 2 = 13.97, P < 0.001). In a Cox multivariate analysis, which included histologic grade, the association between DCIS type and prognosis was lost because of the very close relationship between type and grade. These results support the validity of the new classification and reinforce the view that treatment of pure DCIS should be related to tumor type.

Entities:  

Mesh:

Year:  1994        PMID: 7831533

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  20 in total

1.  Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast.

Authors:  C M Quinn; J L Ostrowski
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

Review 2.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

3.  Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

4.  Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression.

Authors:  Paul Macklin; Mary E Edgerton; Alastair M Thompson; Vittorio Cristini
Journal:  J Theor Biol       Date:  2012-02-09       Impact factor: 2.691

Review 5.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

6.  "Revertant" mammary solid papillary carcinoma in lymph node metastasis.

Authors:  Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 7.  Genome evolution in ductal carcinoma in situ: invasion of the clones.

Authors:  Anna K Casasent; Mary Edgerton; Nicholas E Navin
Journal:  J Pathol       Date:  2016-11-27       Impact factor: 7.996

8.  Heterogeneity of invasive ductal carcinoma: proposal for a hypothetical classification.

Authors:  Baik-Hyeon Jo; Yi-Kyeong Chun
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

Review 9.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

10.  Reproductive and hormonal risk factors for ductal carcinoma in situ of the breast.

Authors:  Lynette S Phillips; Robert C Millikan; Jane C Schroeder; Jill S Barnholtz-Sloan; Beverly J Levine
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.